Press Releases April 1, 2026 08:00 PM

Emergent BioSolutions Participates in Upcoming International Preparedness Conferences

Emergent BioSolutions to engage in multiple international health security and biodefense conferences.

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
EBS

Emergent BioSolutions announced its participation in several upcoming international conferences focused on health security and biodefense, emphasizing the company's commitment to global preparedness against biological threats. The events span from April to June 2026, aiming to strengthen collaboration with governments and industry leaders in medical countermeasures.

Emergent BioSolutions Participates in Upcoming International Preparedness Conferences
EBS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Emergent BioSolutions will attend key global conferences including London Defence, CBRN Research & Innovation, Global Health Security, and BIO International Convention.
  • The company focuses on developing and delivering medical countermeasures against critical biological threats such as smallpox, anthrax, botulism, and Ebola.
  • Participation in these conferences highlights Emergent's role in international health preparedness and biodefense collaboration.

GAITHERSBURG, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global life sciences leader with biodefense and medical countermeasures products, announced today that members of its products business, medical affairs, government and public affairs teams will participate in the following international preparedness conferences:

  • London Defence Conference, April 10-11, London, United Kingdom
  • CBRN Research & Innovation Conference, May 19-21, Arcachon, France
  • Global Health Security Conference, June 9-12, Kuala Lumpur, Malaysia
  • BIO International Convention, June 20-22, San Diego, California, United States

“As the world navigates an increasingly complex health threat landscape, Emergent is committed to working with governments to help protect regional and global security,” said Paul Williams, senior vice president, head of products business, global government and public affairs. “We look forward to engaging with government and industry leaders to discuss how together we can strengthen preparedness and help protect and save lives.”

Emergent specializes in developing, manufacturing and delivering medical countermeasures to governments around the world for security and preparedness. These products support emergency response preparedness and help protect the public from critical threats like smallpox, anthrax, botulism and Ebola. Learn more about how we help protect people worldwide from biological threats at emergentbiosolutions.com/biothreats.

AboutEmergent BioSolutions 
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. 

Investor Contact: 
Richard S. Lindahl 
Executive Vice President, CFO
[email protected] 

Media Contact: 
Assal Hellmer 
Vice President, Communications 
[email protected] 


Risks

  • The effectiveness of Emergent's products in responding to emerging biological threats remains subject to ongoing government evaluations and approvals.
  • Global geopolitical and health security dynamics could impact funding and demand for biodefense countermeasures.
  • Competition in the biodefense and medical countermeasures market may affect Emergent's market share and growth prospects.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026